Who
Stuart A. Arbuckle
Director
Company insider
Files Form 4 as: Director, Rhythm Pharmaceuticals; Director, Praxis Precision Medicines; Director, Alnylam Pharmaceuticals; EVP, COO, Vertex Pharmaceuticals; Director, ImmunoGen; Director, Dare Bioscience.
In numbers
- Trades disclosed
- 556
- Buys
- 0
- Sells
- 102
- Bought
- $0
- Sold
- $139.9M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 4 Sep 2012
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —688 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —478 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —224 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —224 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Stuart A. Arbuckle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.